Impact of age at diagnosis of de novo metastatic prostate cancer on survival
Impact of age at diagnosis of de novo metastatic prostate cancer on survival
复制标题
DOI：
10.1002/cncr.32630
复制
发表时间：
2019-11-26
期刊：
影响因子：
6.2
通讯作者：
Sridhar, Srikala S.
中科院分区：
文献类型：
--
作者：
Bernard, Brandon;Burnett, Colin;Sridhar, Srikala S.
背景诊断前列腺癌时年龄越大，前列腺癌特异性生存率（PCSS）越差。然而，这些研究是在许多延长生命的药物获得批准之前进行的。本研究旨在描述诊断为原发性转移性前列腺癌（mPCa）的当代男性队列的结局，并评估与诊断时年龄的相关性，同时控制已知的预后因素。方法使用监测，流行病学和最终结果登记处来识别2004年至2014年诊断为mPCa的男性。男性按4个年龄组分类：≥ 75岁。计算全因死亡和前列腺癌特异性死亡（PCSM）的中位总生存期、PCSS和限制性平均生存时间。根据年龄组和控制种族、婚姻状况和收入，估计PCSM的多变量和亚分布风险比。结果与年龄≥ 75岁的男性相比，5年时的平均PCSS短6.7个月（95%置信区间[CI]，5.5-7.8个月）。在多变量分析中，年龄≥ 75岁的男性PCSM的发生率比年龄≥ 75岁的男性高49
Background An older age at the diagnosis of prostate cancer has been linked to worse prostate cancer-specific survival (PCSS). However, these studies were conducted before the approval of many life-prolonging drugs. This study was aimed at describing outcomes in a contemporary cohort of men diagnosed with de novo metastatic prostate cancer (mPCa) and assessing associations with the age at diagnosis while controlling for known prognostic factors. Methods The Surveillance, Epidemiology, and End Results registry was used to identify men diagnosed with mPCa from 2004 to 2014. Men were classified by 4 age groups: = 75 years. The median overall survival, PCSS, and restricted mean survival times for any-cause mortality and prostate cancer-specific mortality (PCSM) were calculated. Multivariable and subdistribution hazard ratios for PCSM according to age group and with controlling for race, marital status, and income were estimated. Results Compared with men aged = 75 years experienced a mean PCSS at 5 years that was 6.7 months shorter (95% confidence interval [CI], 5.5-7.8 months). In multivariable analyses, men aged >= 75 years had a 49% increase in the rate of PCSM in comparison with those aged